science park

7/28/2019 Science Park

1/16

MODERN EVOLUTION OF THE

IDEALSCIENCE PARK


2/16


IDEALSCIENCE PARK ADVERTISEMENT FEATURE

PUBLISHING TEAM

Publishing Director

Peter Collins

Publisher

Melanie Brazil

Business Development Manager

Graham Combe

[email protected]

Gloria To

[email protected]

Business Profile Writers

Barbara Nasto

Suzanne Elvidge

Marketing

Samantha Savalio

Production

Stephen Russell

Tom Rose

Jason Rayment

Note: Companies that appear in this

table of contents have paid for their

advertisement features and have final

approval of their content. If you would

like to appear in the next feature please

contact:

Graham Combe,

Business Development Manager

[email protected]

S1 FEATUREModern Evolution of the Ideal Science ParkS5 Wuhan Biolake

S6 BioBay

S8 FEATUREUK BioIncubator Forum: Allied for Challenging TimesS10 AURP The Association of University Research Parks

S11 Wroclaw Technology Park

S12 DuBiotech

S13 Hong Kong Science & Technology Parks Corporation

Contents

MODERN EVOLUTION OF THEIDEALSCIENCE PARK

COVERIMAGEBuilt along the waterfront, the 22 hectare Hong KongScience Park provides 20 state-of-the-art laboratory-fitted buildings offering

220,000 square meters of office space. Fully equipped laboratories and

engineering services are available for hourly rental or on project basis.

Since its inception in 2001, the Park is home to more than 300 technology companies

engaging in integrated circuits and electronics; precision engineering, biotechnology,

green technology and ICT industries. These companies range from start-up, SME to

multinational conglomerates and are both local and overseas owned organisations.


3/16S1

ADVERTISEMENT FEATURE


IDEALSCIENCE PARK

MODERN EVOLUTION OF THE IDEAL

SCIENCE PARKScience Park is a broad sweepingand sometimes ambiguous label.Usually, when the two words areused together they refer to a collec-tion of buildings dedicated to busi-nesses conducting scientic researchor facilitating research that willlead to a commercial application.

Whether they are simple orcomplex, parks are present acrossthe global landscape and forgood reason. According to LuisSanz, International Associationof Science Parks, the number ofscience parks is still growing inthe 21st century and he explainsit is because they t the needs ofthe global knowledge economy.

Sanz is referring to the use ofknowledge technologies (such asbiotechnology, electrical engineer-ing and computer information sys-tems) to produce economic benetsand prompt job creation. Shis inthe global economy have promoted

the perception that fostering aknowledge-based economy will leadto long-term prosperity. oughscience parks are not unique to thebiotechnology industry, they are aubiquitous feature of establishedbiotechnology clusters, burgeoning

clusters and regions aspiringhelp the

industry grow in their backyard.e IASP survey estimates that

biotechnology and the life sciencesrank second among technologysectors and comprise 20% of thecompanies occupying space in thescience parks of the world. is issecond only to Information andCommunication technology (26%).e other sectors are Electronicsand Computers (19%), Agro-food(9%), Environmental (8%), newmaterials (6%), and Pharmaceuticals(5%). Within the US, medical andbiotechnology rank rst at 45.6%and information technology followsat 34.2%. e statistics shoulddemonstrate that the science parkindustry is embraced by the gamutof technical industry. Due to thenature of the industry, this report

will discuss overarching dynamicsof the science park industry whilehoning in the biotechnologyand pharmaceutical industry.

A Bit of Historye modern version of the science

park is a descendent of a largedinosaurthe science city. escience city was a manifestationof eorts to rapidly increaseindustrial research and develop-ment capabilities (R&D) during

World War II. is meant

building a small city from theground up in order to housescientic and technical research.e infamous Manhattan Project

was responsible for the buildingof three within the US. BletchleyPark in the UK and Peenemnde inGermany are two other examples.

While eective at driving somebreakthrough technologies, theremoteness and expense of thescience city eventually gave way toa smaller more manageable model.

Following WWII, returningstudents were ooding intoAmerican universities. Growing tomeet the demand, in turn, creatednancial demands on educationalinstitutions. is socioeconomicclimate led to the emergence ofthe rst university science park.At Stanford University, FrederickTerman (Dean of the School ofEngineering in 1951) is credited

with proposing to lease Stanfords

lands for use as an o ce park,named the Stanford Industrial Park(later Stanford Research Park). Inaddition to the leases providingfunds, locating industry nearby

would create local employmentopportunities for graduatingstudents. e Stanford ResearchPark is thought to be the oldestuniversity-owned research park. esecond, Research Triangle Park

established in 1959, recentlymarked its 50th anniversary.

e early science parks, then,were bridges between academiaand industry, places where the ideasand trained manpower from theuniversities could be deployed tothe advantage of initially largelylocal industry. e universitiescreate or participate in the develop-ment of science parks not only toearn a prot by commercializingresearch discoveries but to establisha dynamic environment for theirgraduates. But it didnt take longfor the science park to beginto have a self-perpetuating lifeof its own. e consequence ofcreating space for high-technologyindustries to thrive created itsown commercial engine thereality was that high-tech parks

were a winning real-estate play.Initially in Boston, biotech rms

moved where they could nd

space, says Peter Abair the Directorof Economic Development ofMassachusetts BiotechnologyCouncil. Genzyme started in adi cult area-self built lab spacelocated in the upper levels ofan o ce building. Early on asymbiosis between public policyand park development is palpable.

In the early 1980s, Kendall

During WWII, governments constructed entire cities to facilitate technological advancement.

This street scene shows housing built for the Manhattan Project at Los Alamos (NM, US)


4/16S2



Square was an underused urbanrenewal area prioritized by thecity o Boston or redevelopment.Te Massachusetts Institute oechnology (MI) became thelandlord and built lab space. Temove marked the convergence onew industry and a public policydecision according to Abair. Sincethen a number o large nationalbiotech developers emerged. Forexample, Alexandria Real EstateEquities, Inc (Pasadena, CA)labels itsel Landlord o Choiceto the Lie Science Industry.Kendall Square is currently hometo several academic and researchbuildings aliated with MI, as

well as over 150 biotechnology andinormation technology frms.

Te development o storiessuch as those at Kendall Square,Stanord and Research rianglePark, spawned other ventures.Developers such as Alexandria inthe USA, or Slough Estates in theUK recognized brain power couldbe readily monetized through the

aegis o the science park. By creatinga stimulating environment orpotentially high-value, high-growthcompany, green- or brown-feldsites could be converted into primerental property to accommodatea churn o commercializable ideasemanating rom the academic sec-tor. From a real-estate perspective,it didnt matter i some o the ideasdidnt work out and the companiesailed: there would be anothergeneration o hopeuls along soon.

What the early science parksestablished were not only a

mechanism or bringing industryand academia together, but amechanism or doing it proftablyand thereore, in a sel-sustainingmanner. According to data romthe International Association oScience Parks, there was a explosiono activity in establishing research

parks in the last two decades othe 20th century. Some 30% o theexisting research parks across theglobe were set up during the 1980sand another 48% were set up in the1990s. A urther 18% began opera-

tion aer the turn o the century.

In the early 1980s, (around thetime when science park ormation

jumped to 30%) the Bayh-Dole Actreormed ederal patent policy by

providing increased incentives orthe diusion o ederally-undedinnovation results; the researchand experimentation (R&E) taxcredit underwrote the internal costo increases in R&E in frms; andthe National Cooperative ResearchAct encouraged the ormation oresearch joint ventures. Numerousstate policies coincided with theadoption o science parks. Anothercontribution to this expansion oactivity was the momentum romhigh-tech real estate businesses.From these early events, recognitionby national, regional or municipalgovernment that the creation andexpansion o science parks couldbe used as a sustainable instrumento industrial development policyat a time o industrial transitionspread. In the UK, the CambridgeScience Park (Cambridge, UK)

was created by rinity College in

response to a national governmentinitiative urging UK universities toexpand their contact with industryin order to increase the paybackrom investment in basic researchin the orm o new technologies.oday the Cambridge Science Parkis home to over 100 companies.

As developed nations movedaway rom traditional heavymanuacturing o the post-WWII

war economy towards cleaner, high-technology industry, the science

park became an economic manage-ment tool or government. Societal,

technological and economicinuences have continued to shapeand meld the science park conceptand the result is a great deal o

variation and increasingly complexversions o the original. In recentdecades, building research parks hasbecome a crucial part o strategy inregional economic development inEurope, China, India and, o course,North America. Te inuence oa successul research and develop-ment (R&D)-based economicdevelopment strategy can lead

to employment growth and new

business creation. Countries andregions have adapted the strategyto replace declining industries,become involved in high-growthindustries in hopes o creating longterm growth, or to create synergiesbetween companies and industries.

Governments and regionsScience parks transgress politicalideology. Te science park isrecognized the world over as animportant element in the ormationo a cluster. Te role o the science

park in cluster ormation hasmade it an attractive ocus or

policymakers, university boardsand land developers due to thelong term potential or growing aknowledge-based economy. Toughthe overarching goal associated

with these parks, growing and

supporting knowledge-basedbusinesses, is universal; regionalinuences are a strong determinanto how these goals are addressed.

Te concept is embracedalong the continuum romcapitalism to communism.

At the outset, it was Americanentrepreneurism that demonstratedthe potential value o the science

park in promoting industry. Incapitalist societies such as the US,Canada and Europe, local andregional inuences are more likely

to contribute to the creation o a

science or research park thoughtthe central governing body might

provide some unds or at the veryleast implement policies thatsupport their development.

As might be expected, Chinamore centralized take on

economic control and industrialdevelopment has impacted theway it approached science parkexpansion. Te nations Science,Innovation and echnology planinvests in the development o

parks within designated economicdevelopment zones while providingavorable conditions (such as taxbreaks) or burgeoning companies

working within them. Accordingto statements made by Xu Luping,a senior ocial at the Ministry oScience and echnology Chinaconsiders science parks to be central

to its eorts to build capacity orinnovation, because university-based researchers are among themost productive in China.

China has instituted a central-ized plan or the location andstatus o its science parks. Chineseuniversities submitted applicationsor science parks, and a panel oexperienced park managers select

where they will be built. Chinacommenced building science

parks at universities in the late1980s, with local governments

and the universities usually

Parc Biocitech (Romainville, France) lled thespace left when Sano merged with Aventis


5/16S3



IDEALSCIENCE PARK

covering the construction costs.A centralized approach is not

unique to China or communism,however. Due to its size and limitedresources, Singapore, a parliamen-tary republic, has also been ableto adopt a centrally-controlledapproach. Te Singapore SciencePark was created in the early 1980s

with support rom the Ministry orade and Investment. oday, thegovernment continues to commitresources and provides policysupport. Biopolis, an internationalresearch and development centerdedicated to the biomedical sci-ences is a maniestation o thatsupport. Optimizing the countrieseducation resources Biopolisis located close to the NationalUniversity o Singapore, theSingapore Polytechnic, the Instituteo echnical Education, theNational University Hospital, theSingapore Science Park, Ministryo Education, INSEAD BusinessSchool, and Fusionopolis. Tiscampus is dedicated to providing

space or biomedical researchand development activities andpromoting peer review andcollaboration among the privateand public scientifc community.

In contrast to the top downapproach, ederal policies in theUS encouraging the growth oscience parks seem to be a thingo the past. In 2010, US Federal

support or unding science parksseems a little harder to come byin the US. Te U.S. CongressmenGabrielle Giords (D -AZ)and Martin Heinrich (D-NM)introduced Te Science ParksResearch and Innovative Newechnologies Act (SPRINAct - H.R.4413). Te legislation

would authorize the Departmento Commerce to establish a $7.5million competitive grants programor the development and construc-tion o new science parks and theexpansion o existing ones. Te billhas sat in the Subcommittee onechnology and Innovation since it

was introduced nearly a year ago.In the US, support is more likely

to be regional or coming rom stateand local governments as well asuniversities. Regions are increas-ingly identifed as important playersin the knowledge- based economy.Regions dier in terms o resources(human, social, technological andfnancial capital) and other actorso competitiveness leading to a great

deal o diversity within the sciencepark industry, and this contributesto the dynamic nature o thescience park industry. Nowhereis regionalism more dynamicand palpable than in Europe.

When it comes to policyimplementation, the EuropeanUnion oen employs subsidiarity,the principle that matters ought

to be handled by the smallest,lowest or least centralizedcompetent authority. While

promoting the development oa knowledge based economy is a

principle agreed upon by all the EUmember states, regions, or moregenerally, the sub-national levelare considered important playersin the knowledge-based economy.Centralized support through theEuropean Framework programmeor Research and echnologicalDevelopment, the Competitivenessand Innovation Programme(CIP) as well as the StructuralFunds can potentially support,is available, however it is up tothe local player to use it wisely.

Te science park in Barcelona is aprime example o local governmentactivities building on support madeavailable by the EU. Montserrat

Vendrell, CEO o BioCA, theregional organization promotingbiotech in Catalonia, describesthat is was structural unds andso loans that made it possible to

build the Barcelona Science Park.Home to 65 biotech companiesand 70 pharmaceutical enterprises,BioRegion o Catalonia is theastest growing biocluster in Spain.Fiy percent o those companiesare located in the science parkaccording to Vendrell who went onto highlight that these companiesnot only beneft rom close

proximity to the research instituteand other added value services madeavailable to companies in the park.

Science parks are a very popularpolicy instruments across theEU. Several can be ound in mostmember states and their numbersare constantly increasing even inregions that did not traditionally

possess a strong R&D base.Also on the local level in the US,

universities are still at the core orthe development o science parksespecially when the idea aligns

with urban development. JohnsHopkins University, recipient o theAssociation o University ResearchParks 2010 Emerging Park Award,is spearheading a long-term urbanredevelopment project to build abiotech park called Te Science +echnology Park at Johns Hopkinsthat promises to revive a verydespondent corner o Baltimore.

Pharmaceutical restructuringand the Science ParkRestructuring o the pharmaceutical

industry has in more than oneinstance created opportunity orpark development. Science parkslocated in Romainville, France andSkokie, Illinois, US have been cre-ated aer acilities were le vacantdue to pharmaceutical companiesmergers or acquisitions. Te IllinoisScience Park now stands whereSearle once conducted its research.

Pharmaceutical company GlaxoSmithKline recently teamed up with theUK government and two regional development organizations to developa park for biotechnology companies near its headquarters in Stevenage


6/16S4



Te lie sciences company waseventually acquired by Pfzer, a NewYork City mainstay. Te land wentrom having a single user to provid-ing inrastructure or 19 companies.Located in a suburb o Paris,Romainville share a similar evolu-tion. Te merger o Sanof-Aventis,meant the site was redundant. Nowit is BIOCIECH approximately100,000 sq. o state-o-the-artacilities specialized to the needso biotechnology companies.

Even more recently, a relativelynew variation o the science

park concept has grown out othe pharmaceutical industry.GlaxoSmithKline (GSK) isdonating land near its UKheadquarters in Stevenage tohouse biotechnology companies.Stevenage Bioscience Catalyst isunded by a partnership o the UKGovernment, GlaxoSmithKline,Te Wellcome rust, echnologyStrategy Board and the Easto England DevelopmentAgency. Te project aims to

create a world leading hub orbiotech companies by operatinga culture o open innovation.

Te 38m development isbeing led by the Department orBusiness, Innovation and Skills,

which has agreed to provide12m. An additional 5m willcome rom the echnologyStrategy Board. In addition to

providing the land GSK will investalmost 11m. Te Wellcomerust has committed 6m and

East o England DevelopmentAgency will provide 4m.

Chairman o the StevenageBioscience Catalyst Board, AllanBaxter, explains: Our vision or thecampus is that its ethos, physicaldesign and provision o access tothe specialist skills and networks oGSK and the Wellcome rust, willstimulate innovation in drug devel-opment and increase the probabilityo successul product development.

The Evolution o Science

Park OferingsGlobalization o the lie scienceindustry and have taken science

parks well beyond their originalbricks and mortar approach androle as a meeting place or academiaand industry. From a starting pointo the most undamental missiona science parks can ulfll, (i.e.,

providing our walls and lab space)science parks, or more specifcallytheir management oces thesedays take on technolog y transer,incubation o new business, devel-

opment o synergistic networks,fnancial support and services,access to capital and constructiono shared resource acilities.

Parks have defnitively takenon new traits and characteristicsand diversifed by providing thedevelopment o shared services.Shared services nurture the develop-ment o new frms. Tese servicesmay come in the orm o providingaccess to equipment that can help

young companies optimize their

limited cash ow. Sometimes thismeans simply taking care o somebasic technical services such powersupply, internet, phone system, realbroadband or the slightly morecomplicated data centre. Othertimes, shared acilities can be morecomplex. For example, BioWin,the health cluster o the Walloniaregion o Belgium is a locationor three cell therapy companies:Bone Terapeutics, specializing in

proprietary bone cell products totreat bone diseases, PrometheraBioSciences developing cell thera-

pies rom stem cells expanded romliver tissue, and Cardio3 Biosciencesspecializing in stem cell therapies totreat cardiovascular disease. Biowinis building a joint regenerativemedicine acility or these compa-nies to share. Te move promisesto help these companies as theynavigate the complex challenges obringing their therapies to market.

Non technical services thatcan now be ound amongst parkmanagement oces include

access to legal expertise, businessdevelopment advice and channelsor government unding. In the caseo India and China, relations withthe government and opening tradechannels also fgure into to serviceoering. Finally, collaborationbetween science parks reect theneed to work eciently in anincreasing globalized lie scienceseconomy. Valerie Ayache, ManagingDirector at the Association or theDevelopment o Bioindustry in theGrenoble (ADEBAG) emphasizedthe importance o networks to

the tiny biocluster. Collaborationwith other science parks andcluster associations throughout theEuropean Union can provide muchneeded access to oreign markets.

An article on science park wouldbe incomplete not to mention theimportance o the bioincubator,a concept that embodies a whole

package o services accompaniedby the great deal o handholdingnecessary to help companies gradu-ate to tenancy in a science park.

Incubators are an essential tool

or economic development, in

which, an increasing number ocommunities are starting to invest.In the EU there are currently around900 business incubators operatingthat are making a signifcant contri-bution to job and wealth creation.Some 40,000 jobs are generatedeach year by incubators alone.

Incubators generate start-upsand serve as a driving orce or newinnovative companies throughhelping them to succeed on themarket. Te most eective incuba-tors developed within Europe haveormed part o broader politicalstrategy to include universityresearch activities, research insti-tutes, and private industry withinspecifc region. o this extent, themost successul incubation modelsare ounded upon regional strengthsand private-public- partnership.

Just this month, the researchcampus Babraham opened asecond incubator acility that is willhouse seven new start ups. Derek

Jones CEO. Babraham Bioscienceechnologies (BB) describes the

practicality o taking away thelaboratory waste and deliveringo gases so that the companies inthe incubator can simply ocuson the science. Te bioincubatorat Babraham has nurtured 32companies that have moved on toscience parks located in the area oCambridge. According to a recentreport complied by NottinghamBiocity, companies tend to be moresuccessul i they spend time in anincubator. Cambridge home to theUKs frst science park and Europeslargest biotechnology cluster

exemplifes a dynamic symbiosisbetween incubator and science

parks. When companies outgrowtheir incubator space at Babrahamthey have several options. Even so,

Jones explains, Finding suitableollow-on space can be a problem.Other parks in the region may havegood acilities, but they may only beable to oer accommodation thatis most appropriate or establishedcompanies. It is a challenge or

young companies to fnd the rightsort o acilities or the next phase o

their growth.

Member of Parliament Julian Huppert (right) and Biotech entrepreneur Sir GregWinter (left) were on hand to help open the new bioincubator building at theBabraham Research Campus


7/16ADVERTISER RETAINS SOLE RESPONSIBILITY FOR CONTENT S5



IDEALSCIENCE PARK

In the centre of Chinas economic

circle, Wuhan Biolake Science

Park, with the foundation of

Chinas top educational and

commercial resources, emerges

to become a powerhouse of

innovation and commercialization

of Chinese Bio-industry. It has

gained worldwide attention.

In the spirit of the adage, Buildit and they will come, an area of15 square kilometers (comparablein size to Heathrow InternationalAirport) was set aside by ChinasNational Development ReformCommission for the constructionof Biolake. Biolake, named for the100 lakes that pepper the capital ofthe Hubei province, will eventuallyform four functional industrial

parks, each dedicated to a sectoron the progressive edges of thehealthcare and biotechnologyindustries. e Wuhan NationalBio-industry Base is the parksfull name. Biolakes plan includesan area for small-businessincubation (that is, innovation),bio-pharmaceutical companies,bio-agricultural enterprises andmedical device companies. A totalof 312 businesses are inhabitants.

As the dust from the constructionsettles, Biolake can boast a coupleof prestigious tenants: the numberone pharmaceutical company, Pzer,and the third-largest genomics

provider, BGI, one of the world'stop genomics research institutes.e year 2010 marks a new agree-ment with BGI, and the new Pzerresearch facility is due to open in2011. Pzer is building a state ofthe art R&D center to supportglobal clinical studies. e Wuhanfacility will function in a similarfashion to the center in Shanghai,

providing support for Phase I toPhase III clinical trial development.

BGI will invest RMB 10 billionto develop a genomics industrialbase at Biolake, and will focus on

research platforms for nucleic acidsand proteomics. According to

Wang Jun, executive president ofBGI, a portion of the investment(RMB 500 million) will be usedfacilitate the industry through thedevelopment of education andtesting facilities, research and a

peta-scale supercomputer centre.Wuhan Biolakes ambitions of

being a catalyst for global growth arenot far o the mark. According toSteve Yang, Vice President of PzerR&D Asia, the primary mission of

the Pzer research center located

there is to support the companysglobal development eorts. Future

plans include fostering domesticinnovation on a local level.

History and IndustryWuhan is a 3,500-year-old cityat the center of China, and manyof the fundamental elementsneeded to support a burgeoningindustry are deeply rooted intothe culture. A rich academictradition exists in Wuhan, the

second-largest intellectual centerin China. Wuhan is home to manyacademic and research institutionssuch as the Huazhong Universityof Science and Technology, WuhanUniversity and Wuhan Universityof Technology. Representativesfrom both Pzer and BGI havementioned they would be drawingfrom the local talent pool. Pzer

plans to employ 200 people withina 3-year period at its local facility.Another attractive characteristicspecic to Pzers mission is that thearea supports the largest hospital

system (107 hospitals) in centralChina. Wuhan is already a hubfor conducting clinical trials.

Trade and the logistics ofinternational exports are hardwired,not only due to the citys longhistory as a transit center, butbecause the optoelectrics andmanufacturing industries have beenoperating internationally in Wuhanfor over 20 years. More recently,the Wuhan East-Lake High-TechDevelopment Zone, or WEHDZ,

was upgraded to a National

Innovation Model Zone, a status

exclusive to Wuhan and Beijing. Itmeans the policy makers of Wuhanhave more freedom to reform andimplement favorable trade andbusiness incentives. For example,Pzer will be given some tax andhousing benets. Another attractivequality is that doing business in

Wuhan is less expensive than Chinascoastal cities. Human resources costsare estimated to be 30% lower.

While the city of Wuhan providesthe necessary infrastructure for

supporting innovative industry,Biolake oers a high level ofsupport for both local and foreignbusinesses. For example, on thenancial front, BioPark will help

with a feasibility study for a busi-ness, provide investment assistanceand, on a regulatory level, willinterface with the State Food andDrug Administration (SFDA) ofChina. Other services include thenecessary business registration,

Visa assistance, HR search servicesrelative to senior management andintellectual property protection.

Biolake will also match businesseswith a manufacturing site, and assistwith land acquisition procedures,application for tax exemptionand governmental funding.

Biolake is at the center of abusiness-oriented ecosystem thatis currently in bloom. In 2009, the210 bio-industrial businesses atBiolake reported a total turnover of20 billion RMB. With the necessarycommitment of land, resources and

public policy in place, the climatefor business growth promises to

remain favorable.

A Legacy in Bloom

CONTACT DETAILS:

James Huang, Director Assistant

Wuhan National Bioindustry Base

Construction and Management Office

Investment Service Centre,

666 Gaoxin Avenue,

Eastlake High-Tech Development

Zone, Wuhan 430075, China

Cell: +86 1355 4202889

Tel: +86 27 87205089

Fax: +86 27 87205011

[email protected]

Wuhan Biolakewww . b i o l a k e . g o v . c n


8/16ADVERTISER RETAINS SOLE RESPONSIBILITY FOR CONTENTS6

MODERN EVOLUTION OF THEIDEALSCIENCE PARK ADVERTISEMENT FEATURE

Travelling to a Cold Spring Harbormeeting on computational biology,emerging infectious diseases, orimmunology in health and diseasesused to mean taking a plane to

JFK or buying a ticket on the LongIsland Rail Road to get to one ofNew York States most picturesqueconference venues. But no more.Since the opening of the CSHAsia, the same style of cutting edge,interactive and democratic meetingsare also taking place in Suzhou,China. e CSH Asia programmebegan with the 1st James WatsonCancer Symposium in April.

e CSH Asia initiativetypies Suzhous international,outward-facing, and expansiveambitions in the life sciences.e 2,500-year-old classical and

well-preserved Chinese city some80 kilometres west of Shanghai isalso home to the Suzhou IndustrialPark (SIP), a joint venture of the

Singapore and Chinese governmentswhich has become a high-tech cityof 600,000 people with around13,000 industry projects making itan established hub for IT, healthcareand semiconductor industries. But itis BioBay, the life science and nano-technology industry park foundedby SIP in 2006 that will benetmost from the CSH Asia meetings.

According to Jennie Chen,BioBays head of marketing, theinux of high-calibre, internationalscientists into Suzhou for themeetings will mean that awareness

of developments at the park willincrease greatly. All will see thecity, and some will visit the parkand get involved with ongoing

projects or even start their own.is, she believes, will benet thelocal scientic community and thecountry. Furthermore, the reciprocalarrangements mean that representa-tives from the companies based atBioBay can meet with governmentleaders and investors at the ColdSpring Harbor Annual Conferences.

e BioBay community is

expanding rapidly. From its

foundation in 2006, BioBay nowboast 168 companies, around 10%of which are either foreign-fundedor foreign-Chinese joint ventures.Around 80% of the companies werefounded by Chinese entrepreneursreturning to their homeland withtechnological capability and intel-lectual property. Over 140 of thecompanies are in the life sciences,largely in drug discovery and

development, diagnostics, medicaldevices or providing contractresearch services. ose 168companies currently employ 2500

people. e expectation within 3years is that BioBay will host around300 companies employing 6000

people and generating a combinedrevenue of around US$2 billion.

is critical mass of commercialactivities is important to the com-

panies on the park. Jim Zhou, thePresident of Stainwei Biotech Inc.,a therapeutic antibody company,

welcomes the emergence of Suzhou

Biobay as an international hub:As more and more new biotechcompanies set-up or relocated herefrom countries such as the USA, wecan act locally, but think globally.

One of those incoming rms isWilmington PharmaTech (WPT),a full process research and develop-ment service company whichoriginated in the USA in February2003. It had two cGMP facilitiesin the USA its headquartersat Pencader Research Center inNewark, Delaware and a smaller

facility at Delaware Technology

Park (also in Newark, Delaware) and its joint venture operaton,

Jiayuan-WPT, in Zhejiang, China.But in April 2010 it opened its new-est site, its process research centerin BioBay, a 30,000 sq facilitymanufacturing active pharmaceuti-cal ingredients and intermediates.

According to WPTs President,Hui-Yin Harry Li, a senior pharmaresearcher with DuPont, DuPont

Merck and Bristol-Myers Squibb inthe USA, BioBay has provided helpthat varies from company registra-tion through routing operation tothe agreement signed in January2010 which brought in $9 millionfrom the investor, the SuzhouGuangda Investment Group.ese practical measures gave thecompany a jump start, he says.

BioBays integrated campusprovides a wide range of facilities,which include standard labs, scaleup standalone buildings, as well

CONTACT DETAILS:

Yuwen Liu CEO

Tel. +86 512 62956666

Fax:+86 512 62956633

Email: [email protected]

BioBay is located in Dushu

Lake Higher Education Town of

Suzhou Industrial Park. Suzhou

Industrial Park (SIP) is one of the

most important cooperation

programs between China and

Singapore, and is committed to

building a globally competitive

high-tech industrial park. BioBayis a key driver for innovation and

a key focus of growth at SIP, and

is a leader in the development

of bio and nanotechnology

throughout China.

Suzhou is the best run, best

organized cluster in China, said

Greg Scott, founder and CEO of

ChinaBio (C&EN Sept.14 2009

page 20). Having attracted 169

companies, BioBay is dedicated

to building a dynamic and

interactive innovation cluster

for talents and experts.

VISION

Innovation Oasis for Life

Science one of the best

destinations for the worlds

most innovative scientists

MISSION

We build our dedicated,

enthusiastic and professionally

capable team to serve all needs

for life science innovation

BioBaywww . b i o b a y . c om . c n

BioBay: connecting internationallyand stimulating growth

A friendly working environment

BioBay buildings in the Suzhou Industrial Park




MODERN EVOLUTION OF THEIDEALSCIENCE PARK

as reserved space for build-to-suitprojects. e campus also has arange of core technical operations

which are made available to BioBaycompanies. Very close to Stainwei,for instance, is a well-equippedantibody core-facility which the

company can use at discounted rates.With access high-end equipmentsuch as ow-cytometry and Biacore,

Jim Zhou reckons that Stainweiuse the facility almost on a dailybasis. is saves a lot in terms of

purchasing power and time, he says.But the clusters support

mechanisms reach well beyondthe provision of buildings andlab space and core facilities.ABGENT, for instance, is aservice company manufacturingbiological reagents and providingcustom services to research marketsboth in China and beyond.

Established in 2009, it producesantibodies, peptides, cell lysates,

proteins, RNAi, and other products,which are then shipped to itsheadquarters in San Diego, US forfurther development or distribution.In 2009, 95% of products wereexported internationally. At itsfoundation ABGENT received alot of support from BioBay whenmoved their Chinese headquarterfrom Shanghai Zhangjiang SciencePark to here; such as 1.5 years

of free rental of an 31,000 sq state-of-art biology and chemistrylab facility and administrative offi ce.

e companys CEO, ChunWu believes that ABGENT mightnot be where it is today withoutBioBay. BioBay is really supportivein companies identifying marketopportunities, he says, and theresources they offer are superb.

Harry Li considers that the parkprovides a wonderful working andresearch environment. For WPTnearby academic laboratories are as

important as BioBay core facilities.e Dushu Lake Higher EducationTown with over ten universitiesand research institutes providesa pool of talented researchersand students. And Li specically

values the new Suzhou Institute

of Nano-tech and Nano-bionics,an institute joint founded by theChinese Academy of Science, andthe governments of Jiangsu Provinceand Suzhou city, which is locatedin Biobay. Equipped with shiny,state-of-the-art instrumentation fornano particle research, the institutecomplements one of WPTs keyresearch areas polymorphism andnano scale cr ystallization research.

Stainwei Biotech used BioBayas a conduit to early-stage funding.e company was originallyfunded in May 2005 by a group ofoverseas physician-scientists andlocal Chinese entrepreneurs. escientic founders and key managers(CEO, CSO) undertook theirdoctoral and post-doctoral researchin the New York area, at Cornell,New York University and theMemorial Sloan-Kettering CancerCenter. Stainwei started opera-tions in Shanghais Zhang-jianghigh-tech park and was originallyformed to produce antibodies andrecombinant immunoglobulin-fusion proteins for research agents

or clinical diagnostics.However, one year aer its foun-dation, Zhou and the other foundersrecognised that those markets wereover-crowded. We made a majordecision, he says, to shi the focusto the discovery and developmentof novel affordable humanizedtherapeutic antibodies in cancer andimmune-related diseases. ingsthen moved very fast. Just 2 monthsaerwards, they had a chancemeeting with the managers of theinvestment group, China-Singapore

Suzhou Industrial Park VenturesCo, Ltd (CSVC) which led to an8 million RMB investment fromCSVC. ree months later, inMay 2007, Stainwei moved itsstaff and projects to BioBay.

Stainwei has tripled its facilities

in the three years since the move toBiobay, from 3,000 to more than10,000 sq feet. It received substan-tial subsidies in rent; and some itskey personnel received monthlystipends from local governmentfunds for almost 2 years. All told,this reduced its monthly outlayssuffi ciently that Stainwei was able to

put most of its invested capital intoR&D. Consequently, its pipelinenow consists of at least seven

pre-clinical therapeutic humanizedantibody-drug candidates, includingsome in-vivo anti-angiogenesisagents developed using its propri-etary Hex humanization and fusion

protein expression technologies.For Suzhou Natong (Nanomed

Devices), a nanotechnology rmspecialising in a revolutionary intra-dermal drug delivery, its location inBioBay came about as a result bothof a technical development coopera-tion with a key nanobiotech clusterand the availability of a variety ofhelpful funding mechanisms.

In 2007, following a three-yearcollaboration with the Technical

Institute of Physics and Chemistryof Chinese Academy of Science,Nanomeds founder and CEO,Bai Xu, a Chinese Canadianreturnee, was awarded a Scienceand Technology Pioneer Award

worth 10 million RMB (US$1.47million) from Suzhou IndustrialPark. is, together with threerounds of funding worth morethan US$ 7 millions allowedthe company to commercializeits intradermal nanoneedle drugdelivery technology, FunctionalMicro Array (FMA). FMA,

with a sharp tip of less than 100nm, is designed to safely and moreeffectively deliver drugs throughskin without pain. It can also deliver

protein drugs that, until now, mustbe delivered by needle injection.

Nanomeds rst product wasapproved in China in 2006 aertwo clinical trials in top Chinesehospitals supervised by PrincipalInvestigator from Harvard MedicalSchool and Mass General Hospital.FMA is the rst regulatoryapproved medical product in the

world based on microneedles.

Aer a review of more than 300nominations, Nanomed was namedone of the 12 nalists for 2010Asia Innovation Awards, together

with IBM Health Solution Laband Microso in a competitionsponsored by e Wall Street

Journal. Nanomed plans to launch

its LiteClear cosmeceuticalsand LidoFast pain managementproducts in 2010, also in China,followed by InsuRite, which

provides basal delivery of insulinfor diabetics without injection.

Nanomed now has 27 employeesin over 1100 sq metres of offi ce,lab and cleanroom space. Bai Xusays that BioBay gives the companya world class infrastructure tosupport its growth and appreciatesthe funding from local governmentand reduced rent. However, thecommercial environment on the

park is also an important factor. Wehave already formed alliances withmore than 10 companies located atBioBay, he says. One of the mostrecent is a co-development signed atthe beginning of 2010 with PegBio,a developer of PEGylated proteindrugs. Nanomeds controlledrelease intradermal drug deliverytechnology provides an alternativeto chemical modication of drugs,shortening development cycles andlowering product risks, leading toextended product lifetime and new

drugs approvable via 505 (b)(2).

WEBLINKS

www.abgent.comwww.wilmingtonpharmatech.comwww.stainwei.cnwww.nanomed-devices.com/en


10/16S8



For small life science companiesin the United Kingdom and forthe specialist incubator unitsthat house and support them, thebusiness ecology is not only chang-ing rapidly but it does so in waysthat are currently uncertain andunpredictable. And that climatemay create a much more concreterole for the UK BioIncubatorForum, an organisation that,until very recently, had merelybeen a coalition of the willing.

Te UK BioIncubator Forumstarted slowly and informallyduring a meeting that took placethree years ago at Biocity, a largeUK bioincubator with some 70companies and over 500 employeesin Nottingham. Biocity is locatedon the site of the former Bootspharmaceutical facility. Wejust invited them [representa-tives from other incubators]along, shut the doors and hada chat says Nick Gostick, theIncubation Manager at BioCity.

One of the reasons for forming

UKBIF is that the drivers forbioincubators are not the same asthose represented by organisationssuch as UK Business Incubation(UKBI) or the broader UK ScienceParks Association (UKSPA). Tescience parks area, in general,has been driven by real estateconsiderations and success thereis assessed by increases in landvalues, rather than by gains to theeconomy. UKBI, for its part, doesaddress economic issues but islargely concerned with incubationto stimulate oce-based activitywhich addresses urban regenera-tion following industrial decline.Before UKBIF, there wasntanywhere for people to get togetherto discuss the joys of operatingexpensive wet-laboratories.

Prior to the meeting at BioCity,the UKs bioincubators hadregarded each other as competi-tors for the same company clients and had acted accordingly.But, says Gostick, this was apreconception that proved not to

be the case. When we went roundthe table, no-one could reallythink of any company that hadmoved between regions becauseone bioincubator was cheaper, orbetter, or bigger than another.

Consequently, the UKBIFcontinued, largely as an informalgrouping that took it in turn tohost a meeting each quarter atwhich they explored opportunitiesfor synergism and sharing goodpractice. Te organisation isnow slightly more formal witha designated Chair DavidHardman at Birmingham SciencePark, Aston and a DeputyChair Glenn Crocker at BioCity,plus a small membership fee tocover joint marketing eorts.

Te economic circumstancesin the UK, and the governmentsresponse to them, are now deninga role for UKBIF. For start-uprms in biology, the recent signalsfrom UK government have beenvery mixed. On the one hand,Vince Cable, Britains Secretary

of State for Business, I nnovationand Skills, wants to make sure thatthe United Kingdom convertsits scientic research ecientlyinto business opportunities. Hesaid as much at a speech at thebeginning of at the beginning ofSeptember given at Queen MaryCollege, University of London.Te key, he says, involves buildingstronger links between the UKsscience and research base and thebusiness community; to createmore spin-out companies; and toprovide a magnet for attractingoverseas investors to the UK. Onthe one hand, the UK governmenthas already announced that theintermediate tier of administrationthat funds most of the incubatorsin the UK, the nine RegionalDevelopment Agencies, will bedemolished by March 2012 at thelatest. Tey are to be replaced, insome functions at least, by LocalEnterprise Partnerships, public-private arrangements of regionalgovernment with industry. It is not

clear how many LEPs there willbe, or what form they will take.What is clear is that they wil l bemore numerous than RDAs 56applications to establish LEPs havebeen made by individual cities,counties, groups of counties, orparts of counties. According to oneinsider, local funding from RDAshas already dried up and thereis no real sign how public sectorfunding will support incubation.Te current crop of LEP candidatesis bidding for a share of around500 million a year, approximately

a quarter of what the RDAs had.David Hardman, the current

chair of the UK BioIncubatorForum, says that UKBIF will havean important role in providingcoalescence to what might other-wise be a very fragmented approachto new business development in thelife sciences. He paints a pictureof UK innovation capacity as alake milieu which contains all thenecessary attributes for companyformation and growth invention,patent law, technical resources,

business skills, team building,

UK BIOINCUBATOR FORUM:

ALLIED FOR CHALLENGING TIMES

TABLE 1: INCUBATOR GROUPS IN UKBIF

INCUBATOR LOCATION TENANTS SPACE M2

Babraham Cambridge 31 7,000

BioCity Nottingham Nottingham 67 12,000

BioPark Hertfordshire Welwyn Garden City 25 4,750

Bradford Bioincubator Bradford 10 -

Cardi Medicentre Cardi 16 1,770

CELS Bioincubator Newcastle upon Tyne 5 372

Colworth Science Park Bedford 16 1,909

Diagnox Oxford 12 279

Imperial Incubator London 21 2,230

Leeds Innovation Centre Leeds 10 2,044

London BioScience Innovation Centre London 29 1,800

Manchester (UMIC) Manchester 23 9,320

MerseyBIO Liverpool 13 1,718

Norwich Bioincubator Norwich 19 1,860

Papworth Cardiothoracic Incubator Cambridge 4 1,300

Queen Mary BioEnterprises Innovation Centre London N/A 3,623

Roslin Biocentre Edinburgh 18 2,000

Sheeld Bioincubator Sheeld 4 2,700

Tetricus Bioscience Incubator Porton Down, Salisbury 6 2,090

York Biocentre York 13 3,000


11/16S9



IDEALSCIENCE PARK

market knowledge, industryexperience, and others. Whenthat lake is divided into RegionalDevelopment Agency ponds, thenmost of the incubators which arefunded through the RDAs areoperating in pretty incompleteenvironments. Incubator andscience park managers commonlyreport that a narrow view fromthe RDA can somewhat stiethe growth of the companies.

Hardman says that this issueis bound to become even moreimportant. As the RDAs disappearand the LEPS arise, he says, wego from ponds to puddles. Temanagers always wanted to ndthe competences from withinthe lake rather than from withinthe pond. Te driver behind theoriginal formation of UKBIFwas to allow incubator managersknow what was going on in otherparks, and to strengthen contacts in other words, to combatthe impact of fragmentation.

wo of the key areas in which

the BioIncubator Forum hopes tosway government thinking bothconcern nance: rstly, the fund-ing of research at universities andother institutions and, secondly,the early stage funding of lifescience companies. In both cases,UKBIF appears to be pushingagainst the current tide, if recentgovernment pronouncementshave been interpreted correctly.

In his September speech, BISMinister Vince Cable gave hisclearest indication yet that therewould be cuts to the UK research

base. He kicked o with preamblethat his department, Business,Innovation and Science, was thelargest in Whitehall without a

protected budget. He revealedthen that the previous [Labour]government was planning cutsof 20-25% in the BIS budget.And for the coup de grace heasserted that that money investedin research was an input, not anoutput, measure, asking can weachieve more with less? A fewmoments later, he reprised thisniggardly sentiment. He cited the2010 OECD innovation reportwhich warned that cutting backpublic investment in support ofinnovation may damage thefoundations of long-term growth,and quoted the massive increases inR&D commitments in the USA,China, Sweden, and Germany.But for the severely nanciallyconstrained UK, Cables questionwas not how large an increase ismanageable but how do we econo-mise without damaging science?A report just launched by BioCityNottingham, Opportunity:UK Life Science Start-up report2010, suggests that any cuts are

likely to have a severe eect onbusiness as well as on science.Opportunity looked at the

start-up life science companiesaround the UK and asked abouttheir distribution, the sciencebase that underpins them, and theavailability of early-stage capital.

One key nding was that thereis a positive correlation betweenthe life science research powerof a university and the number ofspin-out companies it produces.Research power is a criterionfrom the UKs annual Research

Assessment Exercise that indicatesthe number of researchers withworld-class ratings. Linkingresearch power to research

spending, the Opportunity reportsuggests that each UK companyspun-out from a university requiresan additional expenditure of38 million ($57 million). Telesson for policymakers, says thereport, is that if you want toincrease the amount of university

spin-out activity (a surrogate forcommercial activity) the amountof funding for quality researchneeds to dramatically increase.

Te other area in which UKBIFis going to have a hard ght on itshands with government concernsthe funding of start-up companies.In essence, the report points to asignicant geographical imbalancein funding. Tree regions of theUK London, the South-east,and the East attracted over75% of the invested capital instart-ups between 2005 and

2009, despite having less than42% of the companies and lessthan 47% of the research powerin life sciences (see table 2).

Te report argues that the excessof invested capital in the threeregions might be attributed to therelatively high percentage of rmsthere that develop therapeutics,an area that usually requires morenance. But then it asks anothervery pertinent question: why arent

more rms outside the South-eastern corner of the UK develop-ing therapeutics? Apparently over53% of the research power residesthere, so why not a proportionatenumber of therapeutic ventures?Te report argues that these absentrms represent an opportunity lostby the skewing of funding to theregions surrounding the nancialcapital of the UK. Tere is asignicant bias to the South-east,rather than where the researchpower is, says Nick Gostick fromBioCity. Tere is evidence to

back up what everybody knows that its a question of gettingventure capitalists on trains.

Part of the solution, accordingto BioCity, might be to channelfunding through the incubators.We have seen that the companiesare likely to be able to raise moremoney if they are based in incuba-tors, says Gostick. If UKBIFcan make that case strongly togovernment, then it may well havefound an important role for itselfin taking the UK life science sector

forward eciently.

TABLE 2

SE, E AND LONDON OTHER REGIONS

Start-ups 41.59% 58.41%

Investment in start-ups (2005-2009) 75.83% 24.17%

Life Science Research Power 46.57% 53.43

% rms in therapeutics 43% 22%

BioPark (Welwyn Garden City, UK) is partof the BioIncubator Forum network


12/16ADVERTISER RETAINS SOLE RESPONSIBILITY FOR CONTENTS10



AURPwww . a u r p . n e t

e Association of UniversityResearch Parks (AURP) announcestheir 2010 Annual Awards ofExcellence and names VirginiaTech Corporate Research Center(CRC) in Blacksburg, Virginia, the2010 Outstanding Research Park.

e 15th Annual AURP Awardsof Excellence recognize the achieve-ments of outstanding research parksand industry veterans and encouragethe development of best practicesamong research and science parks.

AURP recognizes exceptionalleadership in innovation by honoringuniversity research parks, individualsand companies who are drivinginnovation in their communities,said AURP President, Harold Strong.Among this year's AURP Awards ofExcellence recipients, we are proudto name Virginia Tech CorporateResearch Center the 2010 AURPOutstanding Research Park.

e Outstanding Research/Science Park Achievement Award

recognizes parks that excel in bring-ing technology from the laboratoryto economically viable business activ-ities, thus promoting the growth ofbusinesses, jobs and public revenue.

e Virginia Tech CorporateResearch Center nurtures the devel-opment of technology businesses andresearch centers in an entrepreneurialenvironment, said Dr. Joe Meredith,President of the Virginia Tech CRC.It is an honor to be recognizedas the AURP 2010 OutstandingResearch Park and a testament to thetremendous work and achievements

of our sta and tenant companies.e Virginia Tech CRC has

developed 120 acres adjacent tothe Virginia Tech campus. ereare now 27 buildings in the CRCtotaling approximately 1,000,000square feet. ere are currently over140 private companies and researchcenters in the CRC that employover 2,200 people. e incubator

program, Virginia Tech or VTKnowledgeWorks, is currently work-ing with over 50 start-up companies.

e 2010 Emerging Research/

Science Park is awarded to the

Science and TechnologyPark at Johns Hopkins andNew Eastside Communityin Baltimore, Maryland.rough the translationof lab invention anddiscovery into jobs andeconomic opportunity, theScience and TechnologyPark at Johns Hopkinshas begun to re-establisheconomic opportunity andsecurity in East Baltimore

while reconnecting JohnsHopkins to its community. Four hun-dred and twenty two permanent new

jobs have been created in the Parkand 1,943 total jobs have been gener-ated to date by the development.

e Innovation Award is presentedto Fraunhofer USA, headquarteredin Plymouth, Michigan, withresearch centers located in theDelaware Technology Park and MSquare Research Park. Fraunhoferbridges the resource gaps that

many early-stage technologycompanies encounter when tryingto launch their products to market.Fraunhofers research centers presentcustomers with their unique capa-bilities, outstanding resources andimportant synergistic relations withother Fraunhofer centers, institutes,university partners and specialassociates. e Fraunhofer model is

a signicant innovation approachleading to many technologicalachievements that benet society.ese inventions are commercializedthrough licensing and spin-outs.

e Career Achievement Awardgoes to Jackie Kerby Moore, who hasserved as the executive director ofthe Sandia Science and TechnologyPark since its inception in 1998. is>200-acre technology communityis a liated with Sandia NationalLaboratories in Albuquerque, New

Mexico. In her role as executivedirector, Moore has overseen themanagement, marketing, recruitingof tenant companies, and stakeholderrelations. e Park now servesas home for 31 organizationsemploying more than 2,200 people,and total investment in the Parkexceeds $334 million. Moore isa former president of AURP.

e Leadership Award is pre-sented to Dr. Frank B. Cerra, SeniorVice President for Health Servicesand Dean of the Medical Schoolat the University of Minnesota

in Minneapolis, Minnesota. AsSenior Vice President for HealthSciences for the past 14 years, Cerrahas served as the chief leader andadvocate for the development andexpansion of the University ofMinnesotas Biomedical DiscoveryDistrict. He identied propertysurrounding the existing LionsResearch Building as providingthe opportunity for research spacegrowth in biomedical research,and then led the university andlegislative eort required to secure

bonding funds for the district.

AURP Presents the 2010 Awards

of Excellence in Innovation

CONTACT DETAILS:

Chelsea Simpson,

AURP Marketing Manager

Association of University

Research Parks

6262 N. Swan Road, Suite 100

Tucson, Arizona 85718, USA

Tel: 520-529-2521

Fax: 520-529-2499


The Association of University

Research Parks (AURP) is a

professional association serving

the worlds largest community of

research, science and technology

parks. AURPs mission is to foster

innovation, commercialization

and economic growth through

university, industry and

government partnerships.The AURP membership

includes planned and operating

parks, many of which contain

technology incubators, as

well as various university,

government, not-for-profit and

private companies interested

in high-tech economic

development projects.

The Association of University Research Parks

AURP named Virginia Tech CorporateResearch Center (Blacksburg, Virginia)the 2010 Outstanding Research Park

The Science + Technology Park atJohns

Hopkins (Baltimore, MD, US) receivedthe 2010 Emerging Park Award

AURP Upcoming EventsAURP 2011 Spring TrainingMarch 711, 2011

Tempe, ArizonaAURP BioParks 2011June 25, 2011Washington, D.C.

AURP 2011 InternationalConferenceNovember 30December 2, 2011New Orleans, Louisiana

iParks WebinarsAURP now oersiParks Webinars!Visit www.AURP.net for a listof upcoming Webinars andWebinars ON DEMAND

For more information about AURPconferences, professional developmentopportunities and membership, visit theassociations website at www.aurp.net.





IDEALSCIENCE PARK

Geographically, the Wroclaw

Technology Park is located at

the crossroads of Eastern and

Western Europe as the city sits

closer to Prague and Berlin than it

does to Polands capital, Warsaw.

The Park has been instrumental

in the creation of technology-

based businesses in the area

and facilitating the emergence

of a NutriBioMed cluster

which, industrially, rests at the

crossroads between nutrition,

biotechnology and medicine.

Wroclaw is one of the oldestcities in Poland. In 1998 the areasmunicipality, science sector, andeducational and nancial institutionssaw the wisdom in creating the

Wroclaw Technology Park (WTP)to support and promote the growthof technology-based companies.Since 2003, the year markingthe completion of the parks rstbuilding (Lower Silesian Incubatorfor Science and Technology), WTPhas grown to accommodate 100companies occupying three buildingsand employing over 1,000 people.And, in 2010, the WTP startedconstruction on two new buildings.

WPT oers o ce space, laboratoriesand workshops, conference rooms,guest rooms (for visiting scientists),telecommunications services and

advisory and support servicesfor burgeoning enterprises.

WTP plays an important role inthe development of the businesseslocated in the park. e WTP is a

versatile organization that may takepart in the creation of a company,supply essential equipment, provideinvestment capital or help companiesnd funding, or coordinate thefunding for a consortium of compa-nies with synergistic interests. WTPalso assists companies with the pro-motion of products and services and

with access the international market.

Capitalizing on Innovationsin Nutrition

Within the parks enterprise-nurturing environment, a uniquebiocluster is growing. Capitalizingon the opportunity at the crossroadsof nutrition and human health, theNutriBioMed cluster encompassesinterdisciplinary activities aimedat the improvement of health,quality of life and innovationsassociated with nutrition. Currently,

the cluster encompasses 30Polish companies from the food,pharmaceutical and biotechnologyindustry and six universities locatedin Wroclaw or nearby in Poznan.

In addition to being a hub forspecialized businesses, NutriBioMedserves as a mechanism for stimulat-ing technology transfer and aca-demic entrepreneurship, ultimatelyresulting in the establishment ofspin-o companies focused on prod-uct advancement and innovations.

WPT was instrumental in obtainingfour patents (a h is pending) for

research related to an innovativeapproach to food supplementsthat was conducted at WroclawUniversity of Environmentaland Life Sciences and WroclawUniversity of Economics.

e development of a supplementproduct line designed to help pre-vent so-called civilization diseaseshas attracted WPTs largest invest-ment, over 2.5 million. Financingfor the project came from EU struc-tural funds (20072013) within theOperational Programme Industry

and Enterprise (OPIE, Priority 5.1).

Civilization diseases are disordersresulting from the lifestyle andincreased life expectancy of Westernsociety. Intellectual property for thebusiness venture is held by WPT,local universities and companiesinterested in manufacturing andmarketing the products. e sup-

plements are produced from naturalraw materials (such as eggs andseeds), and the basic compositionof the supplement can be adaptedto address dierent deciencies.A pilot line of products will target

vascular disease, osteoporosis and

impaired immunological responsesto infection. Production of fourdierent products is expected tocommence in 2011.

A Cluster Grows in Poland

CONTACT DETAILS:

Wroclawski Park Technologiczny S.A.

ul. Muchoborska 18

54-424 Wroclaw

Tel: +48 71 798 58 00

Fax: +48 71 780 40 34

e-mail: [email protected]

www.technologpark.pl

www.nutribiomed.pl

Wroclaw Technology Parkwww . t e c h n o l o g p a r k . p l

Wroclaw Technology Park'sBusiness Incubation Center is oneexample of the support the parkprovides to growing businesses.


14/16ADVERTISER RETAINS SOLE RESPONSIBILITY FOR CONTENT



S12

CONTACT DETAILS

For more information about

DuBiotech, or to be part of the

community, visit www.dubiotech.ae

or contact:

Girish Sabari

DuBiotech

Dubai Biotechnology and

Research Park

PO Box: 73000

Dubai

United Arab Emirates

Tel: +971 4 390 2222

Fax: +971 4 390 8444


Launched by His Highness SheikhMohammed bin Rashid AlMaktoum, United Arab Emir-ates (UAE) Vice President,Prime Minister, and Ruler ofDubai, Dubai Biotechnology andResearch Park (DuBiotech) is the

worlds premier free-economiczone dedicated to life sciences.

In alignment with its goal tobe the major life science hub inthe Middle East, DuBiotech hasrapidly grown into a communityof 70 biotechnology, pharmaceuti-cal, medical, scientific equipmentand device companies, and diag-nostic and commercial laborato-ries. Members of the communityinclude global leaders like Pfizer,Amgen, Merck Serono, Bristol-Myers Squibb, Maquet ME, Flores

Valles, Eppendorf and Genzyme.Many small and medium businessesare also part of the community.

DuBiotech has invested in pro-viding infrastructure that offers

specially-tailored facilities to meet alllife sciences industry requirements.

The NucleotideLaboratory ComplexSpanning an area of 256,000 squarefeet, the Nucleotide Complex iscomprised of state-of-the-art labora-tory buildings that are purpose-builtfor scientific and industrial R&D,diagnostics, analytical testing,equipment-training activities andafter sales services. The LEED-certified Core and Shell Lab Spaceof the complex can accommodate up

to 160 laboratory units, which aredesigned to meet class III biosafetystandards and guidelines. The labo-ratory units allow flexibility in layoutand customization, and are equipped

with a dedicated space for a bio-logical safety cabinet and an exhaustsystem to enable the filtering of air.

Warehouse facilitiesDuBiotech offers pre-built unitsdesigned as modules for storage,showroom, distribution, logistics,and manufacturing for the phar-

maceutical and biotechnology

industries. The pre-built units arepart of a complex of 25 warehouses;and each warehouse includes amezzanine floor, which serves asoffices that can be organized usingoffice partitions, along with anindependent kitchen, and visitorsand owners parking. The facilitiesinclude a dedicated loading andunloading dock, with space allocatedin the roadways for moving goods.

The Bio Headquarter TowersWhen completed, this 22-storeytwin headquarter building will serveas an efficient, best-in-class facilityfor life science companies interestedin growing their business in theMiddle East region. The 600,000sq ft headquarters will include ten-ant offices and support services.The building, poised to be one ofthe worlds largest green buildings,received a Design and SustainabilityHonor Award from the AmericanInstitute of Architects (AIA).

Business CenterThe Business Center offers contem-

porary state-of-the-art furnishedoffices and open space workstationsthat cater to small and medium sizecompanies and start-ups. A facil-ity to ease the way for start-ups,the DuBiotech Business Centeroffers competitive total office solu-tions, round the clock services,furnished and equipped facilities,and hassle-free company registra-tions, in addition to various otherbenefits. The Center is ideal for life

sciences-related businesses that wantto start operations immediately.

Investment benefitsDuBiotech is a wise investmentchoice because its companies enjoyunparalleled benefits including 100%foreign ownership, 100% tax freestatus, no corporation tax, incometax or customs duty, no restrictionson capital, trade barriers or quotas,free profit repatriation, competitive

pricing, a one-stop-shop for govern-ment services (such as visas and

permits), and investment options

to suit different business needs.DuBiotech offers its business

partners networking opportuni-ties and assistance to develop theirbusiness, privileged connections

with important stakeholders such

as governmental bodies, financialinstitutions, media, and special-ized professionals, and dedicatedassistance with regulatory matters.

Market contextThe market for the life sciencesindustry in the Middle East andNorth Africa (MENA) is one ofthe few characterized by strongand steady growth. Dubai is thelocation of choice for national andglobal brands, and is an attractive

place to relocate human resourcesbecause it is the commercial hub

of the MENA region. The city issituated at the crossroads of threecontinents, with easy access toa population of over 1.8 billionand offers a high quality of life ina cosmopolitan environment.

DuBiotech is continuing toattract international interest fromboth commercial and public sectors and the 70 companies that havealready chosen the free-economiczone as their home are a testamentto its vision to be a global leader inthe life sciences and biotechnology

industries.

DuBiotech (Dubai Biotechnology

and Research Park) is a 22

million square foot science and

business park based in Dubai,

and the Middle East. Its facilities

include laboratories, warehouses,

commercial and business center

services, land for long term lease

and its flexible accommodation

offers opportunities for bothestablished international

companies and small and medium

enterprises (SMEs). The park

was launched in 2005, and is a

member of TECOM Investments.

DuBiotech: the future

of life sciences in the Middle East

DuBiotech, Dubai, United Arab Emirateswww . d u b i o t e c h . a e





IDEALSCIENCE PARK

Hong Kong Science and

Technology Parks Corporation

(HKSTPC) is a statutory body

set up by the Government

of the Hong Kong Special

Administrative Region.

HKSTPC manages Hong Kong

Science Park, InnoCentre

and three Industrial Estateslocated at Tai Po, Yuen Long

and Tseung Kwan O.

HKSTPC provides technology-

driven infrastructure and support

facilities which include market

focused, clustered laboratory

services. It also provides full

service incubation programs

for start-up companies, and

fosters partnership and

collaboration between industryand universities/applied research

institutes through consulting,

training and research programs.

Hong Kong well known for itsfree economy, international busi-ness environment, simple and lowtax system, and sound protectionof intellectual property rights isnow building on its reputation as aresearch and development engine.Its geographical and historical asso-ciations give Hong Kong not only a

position to establish the city as a key

part of the international scene butalso, of course, unrivalled access tothe rest of China. For many high-tech industries, this relationship hasled to a value chain that stretchesacross the Pearl River Delta (PRD)region, with Hong Kong as alocation for corporate headquartersand research and development(R&D) facilities, while Shenzhenserves as the manufacturing base.Under the Mainland and HongKong Closer Economic PartnershipArrangement (CEPA), an accordlike a free trade agreement, this

value chain is reinforced becausemany Hong Kong goods andservices can enter China tari-free.

Hong Kong is also increasinglyrecognized as an internationaleducation centre, home to world-leading research universities thatare especially strong in life sciencesand biomedical areas. Bibliometricsurveys commissioned by HongKong Science & Technology ParksCorporation (HKSTPC) indicatedthat Hong Kongs biomedicalresearch not only accounts for 20%

of the research published from

China in international journals butit also leads other Chinese regionsin terms of citation criteria. ebroader study in which the citationdata appeared (Capturing the DeltaOpportunity: http://bio.hkstp.org/HKSTPC/bio/index.jsp) identieda number of research projects withcommercialization potential andconcluded that Hong Kong has the

resources to grow a thriving bio-medical cluster that could serve as ahub for the entire HK-PRD region.

Biotechnologyincubation programFor young local growth companiesand for expanding inward investorsin life sciences, Hong Kong SciencePark, managed by HKSTPC,now oers dedicated incubationunits at the Biotech SME Centre.

With phase 2 development of theCentre completed in 2009/10,ready-to-use laboratory units now

number 18 and there have beenadditional investments in sharedequipment to supplement accessto facilities such as meeting roomsand the biotech support laboratory.In addition, each company can beallocated its own wet laboratoryand small o ce. To assist biotechstart-up companies through theirmost vulnerable inception stages,HKSTPC oers a maximumincubation period of 4 years, withrent-free occupation of the rst 800sq of laboratory/o ce space in

the rst year, and reduced rental

in subsequent years. Additionalsupport comes in the form ofsubsidies of up to HK$851,000for 4 years, calculated as 50%to 75% of actual expenses.

Several life sciences sub-clustershave grown within Science Park.ese include groups of companiesin Chinese/herbal medicine, food,medical devices, and regenerativemedicine. e regenerative medi-cine group now represents nearly19% of all the life science compa-nies in the Park due, in part, to the

presence of world class resea rchgroups and easy access to researchmaterials and patient groups. eregenerative medicine and otherlife sciences sub-clusters are alsofully supported by the state-of-the-art shared facilities providinggenome sequencing, genotyping,amplication and quantication;

protein identication, characteriza-tion and quantication; and

ultrasensitive instruments foranalysis such as drugs , metabolites,chemicals, carbohydrates,

proteins steroids, and pest icides.For clinically-oriented

companies, Hong Kong also hasworld-class cl inical trial centersthat are unique in that trial resultsin a number of therapeutic areas areaccepted by both the US Food andDrug Administration (USFDA)and the Chinese State Food andDrug Administration (SFDA).Hong Kong is also establishing aTesting and Certication Centre

for Chinese/Herbal Medicine andFood, a move that complementsthe presence in the Science Parkof companies such as PurapharmInternational (one of the majorSouthern China players inextracted products), Bionorica (aGerman herbal drug company),and major food concerns such asDiageo (a major British purveyorof branded drinks), SeperexNutritionals (a New Zealand-basedleading manufacturer of dairysupplements in Asia Pacic), and

Alimentary Health Asia.

The alpha-rated delta bioregion

CONTACT DETAILS:

Mr. Paul Chan

8/F, Bio-Informatics Centre

No.2 Science Park West Avenue,

Hong Kong Science Park, Shatin,

New Territories, Hong Kong

Tel: +852 2629 6881


http://bio.hkstp.org

Hong Kong Science

& Technology Parks Corporationwww . h k s t p . o r g


16/16

Top Quality Services... imagine the speed ...

from chemistry to biology... enjoy the versatility ...

Since 2001, Abgent has been striving to exceed the highest expectations of

all our customers. Join the thousands supported by our personal attentionand commitment. Visit us at www.abgent.com or call at 1.888.735.7227.

Custom antibodiesmonoclonal, polyclonal and recombinant antibodies

produced in rabbit, mouse, goat, and chicken hosts

for research, diagnostic and therapeutic discoveries

Custom peptidesscales from 1 mg to > 1 kg

lengths from 5 aa to > 100 aa

a varieties of modifications and libraries

Custom proteinsbacterial, baculoviral, and mammalian systems

synthetic genes or amplifed from native libraries

recombinant or isolated from tissue

science park

Documents